Differential expression of tissue factor and tissue factor pathway inhibitor in metastatic melanoma lesions

Pigment Cell Res. 2002 Jun;15(3):212-6. doi: 10.1034/j.1600-0749.2002.01081.x.

Abstract

Tissue factor (TF) is involved in tumor progression and metastatic potency in some malignant tumors and its function is regulated by tissue factor pathway inhibitor (TFPI) therefore the interaction of both molecules is crucial for their functional role. We evaluated the clinical relevance of TF and TFPI expression in benign and malignant melanocytic lesions. Expression of both was examined by immunoperoxidase staining using serial tissue sections in 16 nevi, 34 primary and 15 metastatic melanoma lesions. TF and TFPI were ubiquitously expressed in benign and malignant melanocytic lesions. This finding was confirmed by Western blot analysis using cultured human melanocytes, nevi cells (NCN) and melanoma cell lines. Although TF expression was not associated with malignant transformation and disease progression, TFPI expression in primary and metastatic melanoma lesions was significantly lower and weaker than that in nevi lesions in terms of intensity and percentage of stained cells. In addition, TFPI expression in metastatic lesions was significantly lower and weaker than that of TF. These results suggest that the relative expression of TF to TFPI may play a crucial role in the malignant transformation and metastatic potency in melanocytic cells.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Blotting, Western
  • Cell Division
  • Cells, Cultured
  • Child
  • Disease Progression
  • Female
  • Humans
  • Lipoproteins / metabolism*
  • Male
  • Melanocytes / metabolism
  • Melanoma / metabolism
  • Middle Aged
  • Recombinant Proteins / metabolism
  • Skin Neoplasms / metabolism
  • Thromboplastin / metabolism*

Substances

  • Lipoproteins
  • Recombinant Proteins
  • lipoprotein-associated coagulation inhibitor
  • Thromboplastin